Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia

Author： Prescott Hillary   Kantarjian Hagop   Cortes Jorge   Ravandi Farhad  

Publisher： Informa Healthcare

ISSN： 1472-8214

Source： Expert Opinion on Emerging Drugs, Vol.16, Iss.3, 2011-09, pp. : 407-423

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

FMS-like tyrosine kinase 3 inhibitors: a patent review

By Lee Jongkook   Paek Seung-Mann   Han Sun-Young  

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 4, 2011-04 ,pp. : 483-503

Informa Healthcare

Access to resources Recommend Favorite

Monitoring Chronic Myelogenous Leukemia in the Age of Tyrosine Kinase Inhibitors

By Radich Jerald P.   Oehler Vivian  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 5, Iss. 5, 2007-05 ,pp. : 497-504

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia

By Evangelisti Camilla  

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 8, 2013-08 ,pp. : 921-936

Informa Healthcare

Access to resources Recommend Favorite

Targeting FLT3 Kinase in Acute Myelogenous Leukemia: Progress, Perils, and Prospects

By  

Mini Reviews in Medicinal Chemistry, Vol. 4, Iss. 3, 2004-03 ,pp. : 255-271

Bentham Science Publishers

Access to resources Recommend Favorite

Soluble fms-like tyrosine kinase-1 antibody for diagnosis purposes (WO2010075475)

By Boyaud France   Inguimbert Nicolas  

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 6, 2011-06 ,pp. : 971-975

Informa Healthcare

Access to resources Recommend Favorite